Overview: Geftinat 250 mg Tablets contain Gefitinib (250 mg) and are prescribed as an oral targeted anticancer medicine for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by blocking cancer cell growth signals. Key Benefits: – Targets EGFR pathways to slow tumor progression in NSCLC – Oral dosing for convenient outpatient treatment – Used in patients with confirmed EGFR mutations Composition: Gefitinib (250 mg) How It Works: Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor that blocks receptor signaling involved in cancer cell proliferation, helping control tumor growth in susceptible NSCLC patients. Usage Instructions: – Take exactly as directed by your oncologist – Swallow the tablet whole with water, with or without food – Do not chew or crush the tablet Side Effects: – Diarrhea, rash, acne-like skin reactions – Nausea, vomiting, fatigue – Loss of appetite, mouth sores Precautions: – Not recommended during pregnancy or breastfeeding without medical advice – Monitor liver function tests during treatment – Inform your doctor of all current medications to avoid interactions Storage Instructions: – Store below 30°C in a cool, dry place away from moisture and light Manufacturer: Generic Pharmaceuticals Disclaimer: To be sold by retail on the prescription of a registered medical practitioner only.